MTOR and melanoma: Hambright et al. reported NexrutineR treatment augmented the constitutively elevated oxidative stress markers, reduced proliferation, survival, and colony formation in melanoma cells, which was associated with selective inhibition of activated components of the PI3K/Akt/mTOR pathway [149,150].